Nxera Pharma Co. Ltd. announced that it will receive a milestone payment of US$1.8 million from Centessa Pharmaceuticals. The payment is triggered by Centessa achieving an early development milestone for its investigational orexin receptor 2 (OX2R) agonist, ORX489, as part of a research collaboration between the two companies. The milestone payment will be recognized as revenue in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.